

May 11, 2023

To

**BSE Limited**  
Phiroze Jeejeebhoy Towers, 25<sup>th</sup> Floor, Dalal  
Street, Mumbai - 400 001

**The National Stock Exchange of India Ltd**  
Exchange Plaza,  
Bandra Kurla Complex  
Bandra (E), Mumbai - 400 001

**Scrip Code: 524558**

**Scrip Code: NEULANLAB; Series: EQ**

Dear Sir/Madam,

**Sub: Outcome of Board Meeting**

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors at their meeting held on even date, have considered and approved the following:

**A. Financial Results**

Upon recommendation of the Audit Committee, the Board of Directors have approved the Audited Financial Results (Standalone & Consolidated) as per Indian Accounting Standards (IND AS) for the year ended March 31, 2023 along with Statement of Assets and Liabilities as on March 31, 2023 (enclosed). The Board of Directors took note of the Statutory Auditors' Report on the Audited Financial Results (Standalone & Consolidated) for the year ended March 31, 2023 with unmodified opinion (enclosed).

We would like to state that the Statutory Auditors of the Company, M/s. MSKA & Associates, Chartered Accountants, have issued audit reports with unmodified opinion on the financial statements.

**B. Final Dividend**

Recommended payment of final dividend of Rs. 10/- (100 %) per equity share on a face value of Rs.10 each, for the financial year 2022-23. The dividend will be paid within the statutory timelines upon declaration of the final dividend by the shareholders at the 39th Annual General Meeting (AGM).

The meeting of Board of Directors of the Company commenced at 12:00 p.m. and concluded at 1.45 p.m.


The above information will also be available on the website of the Company at [www.neulandlabs.com](http://www.neulandlabs.com).

This is for your information and records.

Thanking you,

Yours Sincerely,

For Neuland Laboratories Limited

  
  
Sarada Bhamidipati  
Company Secretary

Encl: As above

**Independent Auditor's Report on Standalone Audited Annual Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended**

**To the Board of Directors of Neuland Laboratories Limited**

**Report on the Audit of Standalone Financial Results**

**Opinion**

We have audited the accompanying statement of Standalone annual financial results of **Neuland Laboratories Limited** (hereinafter referred to as 'the Company') for the year ended **March 31, 2023** ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

(i) is presented in accordance with the requirements of the Listing Regulations in this regard; and

(ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2023.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone financial results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

**Management and Board of Directors' Responsibilities for the Standalone Financial Results**

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of the Standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules,



2015, as amended issued thereunder and other accounting principles generally accepted in India and in compliance with the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the financial reporting process of the Company.

#### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to Standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to



the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Other Matters**

The Statement includes the results for the quarter ended March 31, 2023, being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion is not modified in respect of the above matter.

**For M S K A & Associates**  
Chartered Accountants  
ICAI Firm Registration No.105047W



**Amit Kumar Agarwal**  
Partner  
Membership No. 214198



UDIN: 23214198BGXCQP3534  
Place: Hyderabad, INDIA  
Date: May 11, 2023

<b>NEULAND LABORATORIES LIMITED</b>						
11th Floor (5th Office Level), Phoenix IVY Building, Plot No. 573A-III, Road No 82, Jubilee Hills, Hyderabad - 500033						
<b>STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2023</b>						
(Amount in lakhs of ₹, unless otherwise stated)						
Sl. No.	Particulars	Quarter Ended			Year Ended	
		31.03.2023 (Audited) (Refer Note 6)	31.12.2022 (Unaudited)	31.03.2022 (Audited) (Refer Note 6)	31.03.2023 (Audited)	31.03.2022 (Audited)
1	<b>Revenue</b>					
	(a) Revenue from operations	40,707.26	26,925.00	25,587.25	119,119.80	95,107.66
	(b) Other income	806.41	93.31	63.14	974.81	207.67
	<b>Total Income</b>	<b>41,513.67</b>	<b>27,018.31</b>	<b>25,650.39</b>	<b>120,094.61</b>	<b>95,315.33</b>
2	<b>Expenses</b>					
	(a) Cost of materials consumed	13,791.80	13,200.18	9,771.33	48,773.58	43,755.36
	(b) Changes in inventories of finished goods and work-in-progress	3,532.00	(2,644.72)	1,989.42	(950.70)	(1,541.47)
	(c) Employee benefits expense	4,778.38	4,988.89	4,243.57	19,483.84	17,575.85
	(d) Finance costs	428.86	274.47	277.00	1,306.67	1,349.44
	(e) Depreciation and amortisation expense	1,346.99	1,333.62	1,245.23	5,277.62	4,903.64
	(f) Manufacturing expenses	3,542.08	3,388.00	3,236.32	13,555.65	13,136.31
	(g) Other expenses	3,091.30	2,598.29	2,475.35	11,126.66	7,962.22
	<b>Total expenses</b>	<b>30,511.41</b>	<b>23,138.73</b>	<b>23,238.22</b>	<b>98,573.32</b>	<b>87,141.35</b>
3	<b>Profit before tax (1-2)</b>	<b>11,002.26</b>	<b>3,879.58</b>	<b>2,412.17</b>	<b>21,521.29</b>	<b>8,173.98</b>
4	<b>Tax expense</b>					
	(a) Current tax	2,533.62	662.15	703.04	5,039.00	2,042.19
	(b) Deferred tax	17.61	173.80	(473.52)	170.37	(221.55)
5	<b>Profit for the period / year (3-4)</b>	<b>8,451.03</b>	<b>3,043.63</b>	<b>2,182.65</b>	<b>16,311.92</b>	<b>6,353.34</b>
6	<b>Other comprehensive income (net of taxes)</b>					
	(a) Items that will not be reclassified to profit or loss					
	Re-measurement gains/(losses) on defined benefit plans	(60.39)	-	(248.46)	(75.46)	(396.90)
	Net (loss)/gain on equity securities	(168.60)	(167.78)	(0.19)	(334.92)	(302.16)
	Tax on items that will not be reclassified to profit or loss	15.20	-	62.53	18.99	99.89
	<b>Total comprehensive income</b>	<b>8,237.24</b>	<b>2,875.85</b>	<b>1,996.53</b>	<b>15,920.53</b>	<b>5,754.17</b>
7	Paid-up Equity Share Capital (Face value - ₹10 each)	1,290.05	1,290.05	1,290.05	1,290.05	1,290.05
8	Other equity (excluding revaluation reserve)				97,462.53	82,183.49
9	<b>Earnings Per Share (of ₹10 each) (In absolute ₹ terms)</b>					
	(a) Basic (refer note 4)	65.87	23.72	17.01	127.14	49.52
	(b) Diluted (refer note 4)	65.87	23.72	17.01	127.14	49.52
	<b>See accompanying notes to the financial results</b>					



NOTES:

- 1 The financial results for the quarter and year ended 31 March 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 11 May 2023.
- 2 The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The operations of the Company are predominantly related to the manufacture and sale of active pharmaceutical Ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments".
- 4 The EPS for quarters has not been annualised.
- 5 The Board of Directors has recommended a dividend of Rs. 10/- (Rupees Ten) only per equity share of Rs.10 each subject to approval of shareholders for the year ended 31 March, 2023
- 6 The figures for the quarter ended March 31, 2023 and March 31, 2022 are the balancing figures between the audited figures in respect of the full financial year and the published unaudited figures upto nine months of the relevant financial year.
- 7 The previous period figures have been regrouped/rearranged wherever necessary to make it comparable with the current period.



## 8 Statement of Assets and Liabilities

(Amount in lacs of ₹, unless otherwise stated)

Particulars	As at 31.03.2023 (Audited)	As at 31.03.2022 (Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	45,133.77	45,712.21
Right-of-use assets	609.45	899.68
Capital work-in-progress	4,056.58	2,045.71
Investment property	1,934.30	1,965.84
Goodwill	27,946.10	27,946.10
Other intangible assets	130.07	212.02
<b>Financial assets</b>		
(i) Investments	68.31	65.56
(ii) Other financial assets	769.73	583.26
Income tax assets (net)	855.07	519.80
Other non-current assets	396.69	337.03
<b>Total non-current assets</b>	<b>81,900.07</b>	<b>80,287.21</b>
<b>Current assets</b>		
Inventories	27,923.34	26,521.01
<b>Financial assets</b>		
(i) Investments	-	337.68
(ii) Trade receivables	36,176.80	23,432.64
(iii) Cash and cash equivalents	4,495.74	371.84
(iv) Bank balances other than (iii) above	1,368.83	1,526.81
(v) Other financial assets	702.88	429.63
Other current assets	5,366.03	5,305.27
<b>Total current assets</b>	<b>76,033.62</b>	<b>57,924.88</b>
<b>Total assets</b>	<b>157,933.69</b>	<b>138,212.09</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	1,290.05	1,290.05
Other equity	97,546.42	82,267.38
<b>Total equity</b>	<b>98,836.47</b>	<b>83,557.43</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
<b>Financial liabilities</b>		
(i) Borrowings	7,424.59	10,424.79
(ii) Lease liabilities	384.75	693.96
Provisions	983.32	1,145.16
Deferred tax liabilities (net)	5,729.60	5,578.23
<b>Total non-current liabilities</b>	<b>14,522.26</b>	<b>17,842.14</b>
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
(i) Borrowings	4,726.40	12,669.82
(ii) Lease liabilities	309.23	264.63
(iii) Trade payables		
- total outstanding dues of micro and small enterprises	1,135.56	1,621.11
- total outstanding dues of creditors other than micro and small enterprises	16,663.69	10,643.97
(iv) Other financial liabilities	6,546.85	4,816.81
Provisions	152.66	121.31
Other current liabilities	14,003.82	6,674.87
Current tax liability (net)	1,036.75	-
<b>Total current liabilities</b>	<b>44,574.96</b>	<b>36,812.52</b>
<b>Total liabilities</b>	<b>59,097.22</b>	<b>54,654.66</b>
<b>Total equity and liabilities</b>	<b>157,933.69</b>	<b>138,212.09</b>




## 9 Statement of Cash Flow

(Amount in lacs of ₹, unless otherwise stated)

Particulars	Year Ended	Year Ended
	31.03.2023 (Audited)	31.03.2022 (Audited)
<b>Cash flow from operating activities</b>		
Profit before tax	21,521.29	8,173.98
<b>Adjustments to reconcile profit before tax to net cash flow:</b>		
Depreciation and amortisation expenses	5,277.62	4,903.64
Interest income	(155.62)	(99.49)
Loss / (Gain) on sale of property, plant and equipment, net	87.08	180.81
Finance costs	1,306.67	1,349.44
Unrealised foreign exchange (gain)/loss, net	809.89	289.84
Unrealised (gain)/loss on forward contracts	-	(58.65)
Provision towards doubtful trade receivables	466.98	56.79
Provision for employee benefits	(186.96)	(4.45)
<b>Operating cash flows before working capital changes</b>	<b>29,126.95</b>	<b>14,791.91</b>
<b>Movements in working capital:</b>		
Changes in inventories	(1,402.33)	(1,760.24)
Changes in trade receivables	(13,432.79)	(1,710.01)
Changes in other financial assets	(459.98)	(70.66)
Changes in other assets	(40.21)	1,772.76
Changes in trade payables	5,607.93	(3,394.59)
Changes in other financial liabilities	1,747.97	(1,286.52)
Changes in other liabilities	7,062.19	(249.47)
<b>Cash generated from operating activities</b>	<b>28,209.73</b>	<b>8,093.18</b>
Income-taxes paid (net)	(4,356.52)	(2,052.62)
<b>Net cash generated from operating activities (A)</b>	<b>23,853.21</b>	<b>6,040.56</b>
<b>Cash flows from investing activities</b>		
Purchase of property, plant and equipment and other intangible assets	(6,612.74)	(9,769.49)
Purchase of Investments property	-	(101.48)
Proceeds from sale of property, plant and equipment	149.13	43.61
Movement in other bank balances	159.98	166.06
Interest Income received	153.88	108.77
<b>Net cash used in investing activities (B)</b>	<b>(6,149.75)</b>	<b>(9,552.53)</b>
<b>Cash flows from financing activities</b>		
Proceeds from long-term borrowings	309.94	4,512.68
Repayment of long-term borrowings	(3,562.37)	(2,226.07)
Proceeds from/(repayment of) short-term borrowings (net)	(8,105.72)	3,479.54
Interest paid on borrowings	(1,234.07)	(1,275.73)
Dividend paid	(641.49)	(384.90)
Repayment of lease liabilities	(264.62)	(253.20)
Interest on Lease liabilities	(81.23)	(80.10)
<b>Net cash generated/ (used) from financing activities (C)</b>	<b>(13,579.56)</b>	<b>3,772.22</b>
<b>Net increase in cash and cash equivalents during the year (A + B + C)</b>	<b>4,123.90</b>	<b>260.25</b>
Cash and cash equivalents at the beginning of the year	371.84	111.59
<b>Cash and cash equivalents at the end of the year</b>	<b>4,495.74</b>	<b>371.84</b>

Place: Hyderabad  
Date: 11 May 2023

For Neuland Laboratories Limited

  
Dr. D R Rao  
Executive Chairman  
IDIN 0010/7371



**Independent Auditor's Report on Consolidated Audited Annual Financial Results of the Group pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended**

**To the Board of Directors of Neuland Laboratories Limited**

**Report on the Audit of Consolidated Financial Results**

**Opinion**

We have audited the accompanying statement of Consolidated annual financial results of **Neuland Laboratories Limited** (hereinafter referred to as the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended March 31, 2023, ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial information of the subsidiaries, the aforesaid Statement:

(i) includes the annual financial results of Holding Company and the following entities

Sr. No	Name of the Entities	Relationship with the Holding Company
1	Neuland Laboratories K.K., Japan	Wholly Owned Subsidiary
2	Neuland Laboratories Inc., USA	Wholly Owned Subsidiary

(ii) is presented in accordance with the requirements of the Listing Regulations in this regard; and

(iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Group for the year ended March 31, 2023.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group, and of in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Consolidated financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.



We believe that the audit evidence obtained by us and other auditor(s) in terms of their reports referred to in "Other Matter(s)" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

### **Management and Board of Directors' Responsibilities for the Consolidated Financial Results**

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and in compliance with the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

### **Auditor's Responsibilities for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

#### **Other Matters**

1. The Statement includes the financial information of two subsidiaries whose financial information reflect Group's share of total assets of Rs. 772.11 lakhs (before consolidation adjustments) as at March 31, 2023 Group's share of total revenue of Rs. 1,120.59 lakhs (before consolidation adjustments) Group's share of total net profit after tax of Rs. 39.84 lakhs (before consolidation adjustments), and Group's share of total comprehensive income of Rs. 80.48 lakhs (before consolidation adjustments), for the period from April 01, 2022 to March 31, 2023 and Group's net cash outflow of Rs. 132.14 lakhs (before consolidation adjustments) for the year ended as on date respectively, as considered in the Statement. These financial Statements have been prepared in




accordance with the accounting principles generally accepted in their respective countries and which have been audited by other auditor(s) under generally accepted auditing standards applicable in their respective countries. The Holding Company's Management has converted the financial statements of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. These conversion adjustments made by the Management of the Holding Company have not been audited by their auditor(s). Our opinion on the statement, in so far as it relates to the financial information of such subsidiaries located outside India is based on the report of other auditor(s) and the conversion adjustments prepared by the Management of the Holding Company. In our opinion and according to the information and explanations given to us by the Management, these financial information are not material to the Group.

2. The Statement includes the results for the quarter ended March 31, 2023 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion is not modified in respect of the above matters.

**For M S K A & Associates**  
Chartered Accountants  
ICAI Firm Registration No.105047W



**Amit Kumar Agarwal**  
Partner  
Membership No: 214198



UDIN: 23214198BGXCQQ9697  
Place: Hyderabad, INDIA  
Date: May 11, 2023

Neuland Laboratories Limited  
11th Floor (5th Office Level),  
Phoenix IVY Building,  
Plot No.573A III, Road No.82,  
Jubilee Hills, Hyderabad - 500033,  
Telangana, India.

Tel: 040 67611600 / 67611700  
Email: neuland@neulandlabs.com  
www.neulandlabs.com

**NEULAND LABORATORIES LIMITED**  
11th Floor (5th Office Level), Phoenix IVY Building, Plot No. 573A-III,  
Road No 82, Jubilee Hills, Hyderabad - 500033  
**STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2023**

(Amount in lakhs of ₹, unless otherwise specified)

Sl. No.	Particulars	Quarter Ended		Year Ended		
		31.03.2023 (Audited) (Refer Note 7)	31.12.2022 (Unaudited)	31.03.2022 (Audited) (Refer Note 7)	31.03.2023 (Audited)	31.03.2022 (Audited)
1	Revenue					
	(a) Revenue from operations	40,707.26	26,925.00	25,587.25	119,119.80	95,107.66
	(b) Other income	806.42	93.31	63.15	974.82	207.68
	<b>Total Income</b>	<b>41,513.68</b>	<b>27,018.31</b>	<b>25,650.40</b>	<b>120,094.62</b>	<b>95,315.34</b>
2	Expenses					
	(a) Cost of materials consumed	13,791.80	13,200.18	9,771.33	48,773.58	43,755.36
	(b) Changes in Inventories of finished goods and work-in-progress	3,532.00	(2,644.72)	1,989.42	(950.70)	(1,541.47)
	(c) Employee benefits expense	4,953.02	5,162.34	4,396.96	20,178.55	18,247.23
	(d) Finance costs	428.87	274.49	277.03	1,306.71	1,349.51
	(e) Depreciation and amortisation expense	1,346.99	1,333.63	1,245.41	5,277.74	4,904.02
	(f) Manufacturing expenses	3,542.09	3,387.99	3,236.32	13,555.65	13,136.31
	(g) Other expenses	2,902.55	2,410.89	2,306.41	10,378.45	7,248.13
	<b>Total expenses</b>	<b>30,497.32</b>	<b>23,124.80</b>	<b>23,222.88</b>	<b>98,519.98</b>	<b>87,099.09</b>
3	Profit before tax (1-2)	11,016.36	3,893.51	2,427.52	21,574.64	8,216.25
4	Tax expense					
	(a) Current tax	2,535.80	664.69	710.29	5,043.94	2,042.90
	(b) Deferred tax	26.17	173.80	(460.84)	178.94	(208.85)
5	Profit for the period / year (3-4)	8,454.39	3,054.82	2,178.07	16,351.76	6,382.20
6	Other comprehensive income (net of taxes)					
	(a) Items that will not be reclassified to profit or loss					
	Re-measurement gains/(losses) on defined benefit plans	(60.39)	-	(248.46)	(75.46)	(396.90)
	Equity instruments through other comprehensive income	(168.60)	(167.78)	(0.19)	(334.92)	(302.16)
	Tax on items that will not be reclassified to profit or loss	15.20	-	62.53	18.99	99.89
	(b) Items to be reclassified to profit or loss					
	Exchange differences in translating the financial statements of a foreign operations	3.82	13.63	2.74	40.69	6.18
	<b>Total comprehensive income</b>	<b>8,244.42</b>	<b>2,900.67</b>	<b>1,994.69</b>	<b>16,001.06</b>	<b>5,789.21</b>
7	Paid-up Equity Share Capital (Face value - ₹10 each)	1,290.05	1,290.05	1,290.05	1,290.05	1,290.05
8	Other equity (excluding revaluation reserve)				98,035.71	82,676.14
9	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)					
	(a) Basic (refer note 5)	65.90	23.81	16.97	127.45	49.74
	(b) Diluted (refer note 5)	65.90	23.81	16.97	127.45	49.74
	See accompanying notes to the financial results					



*[Handwritten Signature]*

NOTES:

- 1 The financial results for the quarter and year ended 31 March 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 11th May 2023.
- 2 The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The consolidated financial results include results of the following wholly owned subsidiaries:  
(a) Neuland Laboratories Inc., USA  
(b) Neuland Laboratories KK., Japan.
- 4 The operations of the Company and its subsidiaries are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments".
- 5 The EPS for quarters has not been annualised.
- 6 The Board of Directors has recommended a dividend of Rs. 10/- (Rupees Ten) only per equity share of Rs.10 each subject to approval of shareholders for the year ended 31st March, 2023.
- 7 The figures for the quarter ended March 31, 2023 and March 31, 2022 are the balancing figures between the audited figures in respect of the full financial year and the published unaudited figures upto nine months of the relevant financial year.
- 8 The previous period figures have been regrouped/rearranged wherever necessary to make it comparable with the current period.



## 9 Statement of Assets and Liabilities

(Amount in lakhs of ₹, unless otherwise stated)

Particulars	As at 31.03.2023 (Audited)	As at 31.03.2022 (Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	45,133.77	45,712.23
Right-of-use assets	609.45	899.68
Capital work-in-progress	4,056.58	2,045.71
Investment property	1,934.30	1,965.84
Goodwill	27,946.10	27,946.10
Other intangible assets	130.07	212.02
<b>Financial assets</b>		
(i) Investments	52.49	49.74
(ii) Other financial assets	772.52	586.24
Income tax assets (net)	855.07	515.01
Other non-current assets	396.69	337.02
<b>Total non-current assets</b>	<b>81,887.04</b>	<b>80,269.59</b>
<b>Current assets</b>		
Inventories	27,923.34	26,521.01
<b>Financial assets</b>		
(i) Investments	-	337.68
(ii) Trade receivables	36,176.80	23,432.64
(iii) Cash and cash equivalents	4,541.59	509.14
(iv) Bank balances other than (iii) above	1,368.83	1,526.81
(v) Other financial assets	702.88	429.63
Other current assets	5,375.97	5,322.34
<b>Total current assets</b>	<b>76,089.41</b>	<b>58,079.25</b>
<b>Total assets</b>	<b>157,976.45</b>	<b>138,348.84</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	1,290.05	1,290.05
Other equity	98,119.60	82,760.03
<b>Total equity</b>	<b>99,409.65</b>	<b>84,050.08</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
<b>Financial liabilities</b>		
(i) Borrowings	7,424.59	10,424.79
(ii) Lease liabilities	384.75	693.96
Provisions	1,029.09	1,191.43
Deferred tax liabilities (net)	5,829.89	5,669.94
Other non-current liabilities	2.78	2.98
<b>Total non-current liabilities</b>	<b>14,671.10</b>	<b>17,983.10</b>
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
(i) Borrowings	4,726.40	12,669.82
(ii) Lease liabilities	309.23	264.63
(iii) Trade payables		
- total outstanding dues of micro and small enterprises	1,135.56	1,621.11
- total outstanding dues of creditors other than micro and small enterprises	15,964.95	10,117.21
(iv) Other financial liabilities	6,554.38	4,837.12
Provisions	152.66	121.31
Other current liabilities	14,012.33	6,684.46
Current tax liability (net)	1,040.19	-
<b>Total current liabilities</b>	<b>43,895.70</b>	<b>36,315.66</b>
<b>Total liabilities</b>	<b>58,566.80</b>	<b>54,298.76</b>
<b>Total equity and liabilities</b>	<b>157,976.45</b>	<b>138,348.84</b>



*DRK*

## 10 Statement of Cash Flow


(Amount in lakhs of ₹, unless otherwise stated)

Particulars	Year Ended	Year Ended
	31.03.2023 (Audited)	31.03.2022 (Audited)
<b>Cash flow from operating activities</b>		
Profit before tax	21,574.64	8,216.25
<b>Adjustments to reconcile profit before tax to net cash flow:</b>		
Depreciation and amortisation expenses	5,277.74	4,904.02
Interest income	(155.63)	(99.50)
Loss/(Gain) on sale of property, plant and equipment, net	87.08	180.81
Finance costs	1,306.71	1,349.51
Unrealised foreign exchange (gain)/loss, net	809.89	289.84
Unrealised (gain)/loss on forward contracts	-	(58.65)
Provision towards doubtful trade receivables	466.98	56.79
Provision for employee benefits	(187.46)	7.58
<b>Operating cash flows before working capital changes</b>	<b>29,179.95</b>	<b>14,846.65</b>
<b>Movements in working capital:</b>		
Changes in inventories	(1,402.33)	(1,760.24)
Changes in trade receivables	(13,432.79)	(1,710.01)
Changes in other financial assets	(459.79)	(69.65)
Changes in other assets	(33.08)	1,764.72
Changes in trade payables	5,435.95	(3,971.71)
Changes in other financial liabilities	1,735.19	(760.64)
Changes in other liabilities	7,060.89	(250.96)
<b>Cash generated from operating activities</b>	<b>28,083.99</b>	<b>8,088.16</b>
Income-taxes paid (net)	(4,362.80)	(2,049.28)
<b>Net cash generated from operating activities (A)</b>	<b>23,721.19</b>	<b>6,038.88</b>
<b>Cash flows from investing activities</b>		
Purchase of property, plant and equipment and other intangible assets	(6,612.85)	(9,768.60)
Purchase of investments property	-	(101.48)
Proceeds from sale of property, plant and equipment	149.13	43.61
Movement in other bank balances	159.98	166.06
Interest income received	153.89	108.78
<b>Net cash used in investing activities (B)</b>	<b>(6,149.85)</b>	<b>(9,551.63)</b>
<b>Cash flows from financing activities</b>		
Proceeds from long-term borrowings	309.94	4,512.68
Repayment of long-term borrowings	(3,562.37)	(2,226.07)
Proceeds from/(repayment of) short-term borrowings (net)	(8,105.72)	3,479.54
Interest paid on borrowings	(1,234.09)	(1,275.80)
Dividend paid	(641.49)	(384.90)
Repayment of lease liabilities	(264.62)	(253.20)
Interest on Lease liabilities	(81.23)	(80.10)
<b>Net cash generated/ (used) from financing activities (C)</b>	<b>(13,579.58)</b>	<b>3,772.15</b>
<b>Net increase in cash and cash equivalents during the year (A + B + C)</b>	<b>3,991.76</b>	<b>259.40</b>
Cash and cash equivalents at the beginning of the year	509.14	243.56
Effect of exchange rate changes on cash and cash equivalents	40.69	6.18
<b>Cash and cash equivalents at the end of the year</b>	<b>4,541.59</b>	<b>509.14</b>

For Neuland Laboratories Limited



Dr. D R Rao  
Executive Chairman  
(DIN 00107737)



Place: Hyderabad  
Date: 11 May 2023

